{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tax+Conditions", "query": { "intervention": "Tax Conditions" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tax+Conditions&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T05:53:07.034Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07581041", "title": "Studying the Impacts of Higher Taxes and Bans on Electronic Cigarettes to Improve Public Health", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Tobacco-Related Carcinoma" ], "interventions": [ { "name": "Discrete Choice Study", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 3400, "start_date": "2026-08-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-09-03T05:53:07.034Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07581041" }, { "nct_id": "NCT06795997", "title": "Tobacco/Nicotine Purchase Patterns Across SES", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Smoking Behaviors", "Smoking, Non-Tobacco Products", "Smoking, Cigarette" ], "interventions": [ { "name": "Tax Conditions", "type": "BEHAVIORAL" }, { "name": "Control Condition", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Virginia Polytechnic Institute and State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 663, "start_date": "2024-12-16", "completion_date": "2025-03-25", "has_results": false, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-09-03T05:53:07.034Z", "location_count": 1, "location_summary": "Roanoke, Virginia", "locations": [ { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06795997" }, { "nct_id": "NCT05257408", "title": "Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Neoplasm", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Nab-paclitaxel 80 mg/m^2", "type": "DRUG" }, { "name": "Relacorilant 150 mg once daily (QD)", "type": "DRUG" }, { "name": "Nab-paclitaxel 100 mg/m^2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 381, "start_date": "2022-06-29", "completion_date": "2026-03", "has_results": false, "last_update_posted_date": "2025-04-16", "last_synced_at": "2026-09-03T05:53:07.034Z", "location_count": 44, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Irvine, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05257408" }, { "nct_id": "NCT06346392", "title": "AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "AZD0901", "type": "DRUG" }, { "name": "Ramucirumab+ paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "TAS-102", "type": "DRUG" }, { "name": "Apatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 594, "start_date": "2024-03-04", "completion_date": "2026-10-14", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-03T05:53:07.034Z", "location_count": 26, "location_summary": "Mobile, Alabama • Tucson, Arizona • Duarte, California + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06346392" }, { "nct_id": "NCT02412722", "title": "A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-hematologic Malignancy" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2015-03-26", "completion_date": "2018-05-31", "has_results": true, "last_update_posted_date": "2020-02-28", "last_synced_at": "2026-09-03T05:53:07.034Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Sarasota, Florida • Oklahoma City, Oklahoma + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02412722" }, { "nct_id": "NCT05370313", "title": "The Impact of Innovative Tax Proposals on Purchase Patterns", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cigarette Smoking" ], "interventions": [ { "name": "Market Price Condition (control)", "type": "BEHAVIORAL" }, { "name": "Tobacco Parity Tax Condition", "type": "BEHAVIORAL" }, { "name": "Nicotine-Content Tax Condition", "type": "BEHAVIORAL" }, { "name": "Harm-Reduction Tax Condition", "type": "BEHAVIORAL" }, { "name": "Modified Risk Tobacco Product (MRTP) Tax Condition", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Virginia Polytechnic Institute and State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 285, "start_date": "2023-04-11", "completion_date": "2025-06-10", "has_results": false, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-09-03T05:53:07.034Z", "location_count": 2, "location_summary": "Buffalo, New York • Roanoke, Virginia", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05370313" }, { "nct_id": "NCT06906341", "title": "Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Neoplasms", "Endometrial Cancer" ], "interventions": [ { "name": "Relacorilant 150 mg once daily (QD)", "type": "DRUG" }, { "name": "Nab-paclitaxel 80 mg/m^2", "type": "DRUG" }, { "name": "Bevacizumab 10 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 270, "start_date": "2025-04-11", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-03T05:53:07.034Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06906341" }, { "nct_id": "NCT07042373", "title": "Effects of Tobacco Abuse Liability-dependent Taxes in the ETM", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cigarette Smoking Behavior" ], "interventions": [ { "name": "Control", "type": "BEHAVIORAL" }, { "name": "Product Category Score", "type": "BEHAVIORAL" }, { "name": "Product Category Rank", "type": "BEHAVIORAL" }, { "name": "Product Tiers", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Virginia Polytechnic Institute and State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 51, "start_date": "2026-07-31", "completion_date": "2027-04-07", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-09-03T05:53:07.034Z", "location_count": 1, "location_summary": "Roanoke, Virginia", "locations": [ { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07042373" }, { "nct_id": "NCT03154294", "title": "Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "TAK-228", "type": "DRUG" }, { "name": "TAK-117", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avera McKennan Hospital & University Health Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2017-07-06", "completion_date": "2022-11-20", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-09-03T05:53:07.034Z", "location_count": 1, "location_summary": "Sioux Falls, South Dakota", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03154294" }, { "nct_id": "NCT07259317", "title": "Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma", "Carcinoma, Pancreatic Ductal" ], "interventions": [ { "name": "Relacorilant", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-01-27", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-03T05:53:07.034Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Orange, California + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Goshen", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07259317" } ] }